1. Home
  2. BCAL vs CTMX Comparison

BCAL vs CTMX Comparison

Compare BCAL & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern California Bancorp

BCAL

Southern California Bancorp

HOLD

Current Price

$17.61

Market Cap

578.3M

Sector

Finance

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$4.44

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCAL
CTMX
Founded
2001
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
578.3M
596.2M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
BCAL
CTMX
Price
$17.61
$4.44
Analyst Decision
Buy
Strong Buy
Analyst Count
3
10
Target Price
$20.50
$11.90
AVG Volume (30 Days)
158.4K
9.4M
Earning Date
04-23-2026
03-16-2026
Dividend Yield
2.31%
N/A
EPS Growth
777.27
N/A
EPS
1.93
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.67
$27.22
P/E Ratio
$8.98
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$11.88
$0.40
52 Week High
$20.47
$8.21

Technical Indicators

Market Signals
Indicator
BCAL
CTMX
Relative Strength Index (RSI) 42.23 44.37
Support Level $16.87 $3.55
Resistance Level $19.31 $6.20
Average True Range (ATR) 0.45 0.60
MACD -0.02 -0.07
Stochastic Oscillator 46.43 3.23

Price Performance

Historical Comparison
BCAL
CTMX

About BCAL Southern California Bancorp

California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through partnerships with its clients. The company has one operating segment: Commercial Banking.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: